FIGURE
Fig. 2
- ID
- ZDB-FIG-220719-62
- Publication
- Bär et al., 2022 - Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer
- Other Figures
- All Figure Page
- Back to All Figure Page
Fig. 2
Real-time measurements of liver cancer and cholangiocellular carcinoma cell proliferation. Dose- and time-dependent effects of bb on (A) HepG2, (B) Huh7, (C) TFK1 and (D) EGI1 cell proliferation as assessed by the iCELLigence real-time monitoring system. Data show the cell viability index measured over 48 h after the application of broxbam. Representative graphs out of three independent experiments were shown for each cell line. Bb, broxbam. |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Int. J. Oncol.